31 |
|
New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003
|
Golec, J.; Vernon, J. A.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
32 |
|
The truth about the drug companies, by Marcia Angell, Random House: New York, 2004. xx +305 pp., $24.95
|
Scherer, F. M.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
33 |
|
The cost of biopharmaceutical R&D: is biotech different?
|
DiMasi, J. A.; Grabowski, H. G.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
34 |
|
Commentary
|
Philipson, T. J.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
35 |
|
Generic competition and market exclusivity periods in pharmaceuticals
|
Grabowski, H. G.; Kyle, M.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
36 |
|
Determinants of drug prices and expenditures
|
Comanor, W. S.; Schweitzer, S. O.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
37 |
|
Commentary
|
Golec, J.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
38 |
|
Commentary
|
DiMasi, J. A.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
39 |
|
Notorious murders, black lanterns, & moveable goods: the transformation of Edinburghs underworld in the early nineteenth century, by Symonds, D. A., Series on International Political and Economic History, University of Akron Press: Akron, OH; 2006, xiv+180pp., USD 39.95 (cloth).
|
Shughart, W. F.
|
John Wiley & Sons, Ltd
|
2007
|
|
|
40 |
|
Bank monitoring, managerial ownership and Tobins Q: an empirical analysis for India
|
Ghosh, S.
|
John Wiley & Sons, Ltd
|
2007
|
|
|